AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Entry into a Material Definitive Agreement
Item1.01.
| Entry into a Material Definitive Agreement. |
On March 28, 2017, AVEO Pharmaceuticals, Inc. (the Company)
entered into a purchase agreement (the Underwriting Agreement)
with Piper Jaffray Co. (the Underwriter), relating to an
underwritten public offering of 30,000,000 shares (the
Underwritten Shares) of the Companys common stock, par value
$0.001 per share (the Common Stock). All of the Underwritten
Shares are being sold by the Company. The public offering price
of the Underwritten Shares is $0.50 per share, and the
Underwriter has agreed to purchase the Underwritten Shares from
the Company to the Underwriting Agreement at a price of $0.465
per share. After underwriting discounts and commissions and
estimated offering expenses, the Company expects to receive net
proceeds from the offering of approximately $13.5 million. Under
the terms of the Underwriting Agreement, the Company has granted
the Underwriter an option, exercisable for 30 days, to purchase
up to an additional 4,500,000 shares of Common Stock (the Option
Shares and, together with the Underwritten Shares, the Shares) at
the public offering price less the underwriting discounts and
commissions.
The Underwritten Shares and any Option Shares will be issued to a
shelf registration statement on FormS-3 that was filed with the
Securities Exchange Commission (SEC) on May7, 2015 and declared
effective by the SEC on May26, 2015 (File No.333-203932). A
prospectus supplement relating to the offering has been filed
with the SEC. The closing of the offering is expected to take
place on March31, 2017, subject to customary closing conditions.
A copy of the Underwriting Agreement is attached as Exhibit 1.1
hereto and is incorporated herein by reference. The foregoing
description of the Underwriting Agreement does not purport to be
complete and is qualified in its entirety by reference to such
exhibit.
A copy of the legal opinion and consent of Wilmer Cutler
Pickering Hale and Dorr LLP relating to the Shares is attached as
Exhibit5.1 hereto.
| Item8.01. | Other Events. |
The full text of the press release announcing the pricing of the
underwritten public offering on March28, 2017 is attached as
Exhibit99.1 hereto and is incorporated herein by reference.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
See the Exhibit Index which immediately follows the hereto, which
Exhibit Index is incorporated herein by reference.
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15). AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Recent Trading Information
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) closed its last trading session down -0.077 at 0.570 with 5,298,282 shares trading hands.
